Conferences EASL2017
Other Infections
EASL 2017: Albumin Reduces Complications of Decompensated Cirrhosis and Improves Survival
- Details
- Category: Decompensation & ESLD
- Published on Wednesday, 03 May 2017 00:00
- Written by Liz Highleyman
Long-term administration of human album was associated with fewer serious complications, less hospitalization, better quality of life, and longer survival for people with decompensated liver cirrhosis, according to a report at the EASL International Liver Congress last month in Amsterdam.
EASL 2017: Besifovir and Tenofovir Exalidex Look Promising for Hepatitis B
- Details
- Category: Experimental HBV Drugs
- Published on Wednesday, 03 May 2017 00:00
- Written by Liz Highleyman
A pair of investigational nucleotide analog antivirals were shown to be active against hepatitis B virus (HBV) with minimal potential for kidney and bone toxicity, researchers reported at the EASL International Liver Congress last month in Amsterdam. Besifovir is in Phase 3 clinical trials, while tenofovir exalidex is in early development.
EASL 2017: WHO Releases Global Hepatitis Report
- Details
- Category: HBV Epidemiology & Mortality
- Published on Monday, 01 May 2017 00:00
- Written by WHO
An estimated 325 million people worldwide are living with chronic hepatitis B or hepatitis C, according to a new report from the World Health Organization (WHO) released at the EASL International Liver Congress last month in Amsterdam.Most lack access to testing and treatment, and therefore are at risk for liver disease progression, liver cancer, and death.
EASL 2017: Triple Combination Cures Most Hepatitis C Patients with Prior DAA Failure
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 01 May 2017 00:00
- Written by Liz Highleyman
Almost all people with genotype 1 hepatitis C who were previously unsuccessfully treated with a course of interferon-free direct-acting antiviral therapy achieved sustained response when retreated with a 3-drug combination being developed by Merck, researchers reported at the EASL International Liver Congress last month in Amsterdam.
EASL 2017: EASL Releases Updated Hepatitis B Guidelines at International Liver Congress
- Details
- Category: HBV Treatment Guidelines
- Published on Tuesday, 25 April 2017 00:00
- Written by Liz Highleyman
The European Association for the Study of the Liver (EASL) presented revised clinical practice guidelines for the management of hepatitis B virus (HBV) infection -- the first update since 2012 -- during a special session at its International Liver Congress last week in Amsterdam. For the first time the guidelines include tenofovir alafenamide (TAF) and present evidence about when and how to stop antiviral therapy.
EASL 2017: Generic Hepatitis C Drugs Continue to Produce High Cure Rates
- Details
- Category: Approved HCV Drugs
- Published on Monday, 01 May 2017 00:00
- Written by Keith Alcorn
Treatment with generic versions of direct-acting antiviral drugs (DAAs) for hepatitis C continues to produce similar cure rates to those reported in clinical trials of brand-name drugs, James Freeman reported last month at the EASL International Liver Congress in Amsterdam.
EASL 2017: Switching to TAF for Hepatitis B Improves Kidney Function and Bone Loss
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 25 April 2017 00:00
- Written by Liz Highleyman
People with hepatitis B who switched from the old tenofovir disoproxil fumarate (TDF) to the new tenofovir alafenamide (TAF) saw improvements in kidney function biomarkers and recovery of bone loss, researchers reported at the EASL International Liver Congress last week in Amsterdam.
EASL 2017: Hepatitis C Treatment Allows 1 in 4 to Come Off Liver Transplant Waiting List
- Details
- Category: Liver Cancer/HCC
- Published on Monday, 01 May 2017 00:00
- Written by Keith Alcorn
Around a quarter of people with hepatitis C and decompensated cirrhosis came off liver transplant waiting lists in Europe after direct-acting antiviral (DAA) treatment, and very few had any subsequent liver-related problems during 15 months of follow-up, Luca Belli reported on behalf of the ELITA study investigators at the EASL International Liver Congress last month in Amsterdam.
EASL 2017: New AbbVie Hepatitis C Combination Cures 99% of People with Cirrhosis
- Details
- Category: Experimental HCV Drugs
- Published on Saturday, 22 April 2017 00:00
- Written by Keith Alcorn
A new pangenotypic direct-acting antiviral combination developed by AbbVie is highly effective in curing hepatitis C in people with cirrhosis, achieving a 99% cure rate after 12 weeks of treatment with minimal side effects, Xavier Forns reported on behalf of the EXPEDITION-1 study investigators at the International Liver Congress this week in Amsterdam.
More Articles...
- EASL 2017: Norfloxacin Reduces Risk of Death for People with Decompensated Cirrhosis
- EASL 2017: Children with Hepatitis C Respond Well to Sofosbuvir/Ledipasvir
- EASL 2017: AbbVie Combination Cures Most People with Genotype 3 Hepatitis C
- EASL 2017: Curing Hepatitis C Reduces Cardiovascular Risk
- EASL 2017: European HCV Treatment Access Survey Shows Big Variations in Eligibility
- EASL 2017: Direct-Acting Antivirals for Hepatitis C Not Linked to Higher Liver Cancer Risk
- EASL 2017: Nivolumab Increases Survival for People with Advanced Liver Cancer
- EASL 2017: International Liver Congress Starts This Week in Amsterdam
Web Design and Development by